Dr. Murphy joins the company with over twenty years of experience in Class I, II, and III medical devices and implantables and has been instrumental in bringing numerous new devices to commercialization. As a member of GTX’ leadership team, Dr. Murphy will be responsible for leading and executing the company’s technology strategy and advancing its neuromodulation product portfolio, which is designed to improve the functional recovery of people with spinal cord injuries (SCI).
by eazee-designstudio
Dr. Dukes has amassed over 20 years in leadership roles at large pharmaceutical and biotechnology companies. As Themis transitions towards rapidly ramping up the development of a coronavirus vaccine candidate towards the clinic in response to the global pandemic and being prepared to supply the initial stockpiles of its vaccine, Dr. Dukes’ background will further enhance the range of experience on the Company’s Board.
STipe Therapeutics announced the appointment of seasoned industry experts: “Both Natalie and Richard are highly experienced industry executives who bring a wealth of international drug development and approval expertise to STipe,” said Dr Claus Elsborg Olesen (CEO). “We are developing novel cancer therapies and I look forward to drawing on their extensive experience as we prepare for the selection of a lead candidate for clinical development.”
Wellington Partners today announced a seed investment into newly founded SIRS Therapeutics, Munich, Germany. With the investment, SIRS has secured the joint ownership with Austrian F4 Pharma of all rights on FX06, a fibrin-derived peptide for treatment of patients with acute respiratory distress syndrome (ARDS) and systemic inflammatory response syndrome (SIRS), including patients with underlying COVID-19 infection.
ImCheck Therapeutics has dosed the first patient in a Phase I/IIa clinical trial evaluating ICT01, a first-in-class gamma delta T cell-activatingmonoclonal antibody targeting the extracellular domain of Butyrophilin 3A. EVICTION (EValuation of ICT01 in Immuno-ONcology) is a first-in-human, two-part, open-label clinical trial to assess the safety, tolerability and activity of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced, relapsed/refractory cancer, including both solid and hematologic tumors that express BTN3A.
Nature Biotechnology has published a study demonstrating Carisma's foundational technology evaluating the potential of human chimeric antigen receptor macrophages (CAR-M) for cancer immunotherapy. The preclinical findings indicate that CAR-M therapy could overcome the key challenges that cell therapies have encountered with solid tumors – limited trafficking to the tumor site, an immunosuppressive tumor microenvironment, and the heterogeneous expression of tumor-associated antigens.
ImCheck Therapeutics, a biotech company developing a first-in-class antibody to activate gamma delta (γδ)T cells in a range of cancer indications and a portfolio of novel immunotherapies for the treatment of cancer and autoimmune diseases, announced today the closing of a $53 million (€48 million) Series B financing round. The proceeds of the Series B will be used to fund the initial clinical trial for ImCheck’s first-in-class monoclonal antibody ICT01, to further expand the company’s broad pipeline of immunomodulators targeting the butyrophilins super-family and to bring additional immuno-oncology antibody programs into the clinic.
eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of safe and effective human-compatible organs to address the global organ shortage, today announced the successful completion of a $100 million Series B financing. The financing was led by Fresenius Medical Care Ventures, with participation from new investors including Leaps by Bayer and Wellington Partners. Existing investors including, but not limited to, ARCH Venture Partners, Biomatics Capital, Alta Partners, and Khosla Ventures all participated.
UroMems has received the 2019 Prix Galien USA Med’Start-Up Award for its collaboration with the Mayo Clinic to design a clinical study for a novel medical device to treat patients with stress urinary incontinence (SUI). The UroMems eAUS device, protected by over 70 patents, is based on the latest technological advances in the field of embedded intelligent software and micro-technologies. It addresses the significant unmet need for a safe, effective, reliable, and seamless solution to treat SUI.
GTX medical and NeuroRecovery Technologies today announced their merger to create a leading global company committed to developing novel neuromodulation therapies to improve functional recovery of people with Spinal Cord Injuries (SCI). The merged entity will be known as GTX medical BV. The Christopher & Dana Reeve Foundation will be a shareholder in the merged company, alongside current investors including LSP, Inkef, Wellington Partners and GIMV. Ian Curtis will join the Board of Directors.
